As part of the deal, CHL acquired the intellectual property, copyrights and brand assets of Mirisk, which were previously owned by Aviir.

Cleveland HeartLab president and CEO Jake Orville said: "The Mirisk acquisition further illustrates CHL’s commitment to commercializing scientifically proven and medically relevant tests.

"CHL has a strong history of innovation and this acquisition further advances our mission of aiding clinicians in identifying risk and reducing cardiovascular events."

The tool has been developed to determine a patient’s potential long-term risk of a heart attack. It has been validated in an eight-year, 5,000 patient clinical trial.

Mirisk holds the capability to determine an individual’s probability of experiencing a heart attack within a five-year timeframe, and uses proprietary algorithm to analyze key blood proteins associated with the development of vulnerable plaque.